COVID-19 Prompts WHO To Propose Revisions To GMPs For Investigational Drugs Guideline
WHO Also Proposes GMPs For R&D Facilities
Accelerated development of COVID-19 products prompts World Health Organization to revise a guideline on good manufacturing practices for investigational drugs and propose a new guideline applying GMP principles to R&D facilities.
You may also be interested in...
COVID-19 Spurs WHO To Revise Guidance On Technology Transfers
The WHO proposes to revise 2011 guidance on technology transfers to ease the hand-off of COVID-19 drugs and vaccines from research and development facilities to commercial sites.
COVID-19 Prompts WHO To Waive Onsite Prequalification Inspections
Agency describes criteria for waiving routine prequalification inspections for existing drugs and vaccines as well as new products in light of COVID-19.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”